NUVATION BIO INC (NUVB)

Company Profile

Nuvation Bio, Inc. is a biopharmaceutical company tackling some of the unmet needs in oncology by developing differentiated and novel therapeutic candidates. The company is headquartered in San Francisco, California and currently employs 53 full-time employees. The company went IPO on 2020-07-01. The firm is focused on developing differentiated and novel therapeutic candidates. Its proprietary portfolio includes mechanistically distinct oncology therapeutic product candidates, each targeting some of the difficult-to-treat types of cancer. The Company’s clinical-stage product candidate, NUV-868, is a BD2-selective oral small molecule bromodomain and extra terminal (BET) inhibitor. NUV-868 inhibits the protein BRD4, a member of the BET family that epigenetically regulates a number of important proteins that control tumor growth and differentiation, including oncogenes such as c-myc. The company has designed NUV-868 to reduce the therapeutic limiting toxicities of BRD4 inhibitors in development by optimizing BD2 versus BD1 selectivity. Its drug-drug conjugate (DDC) platform is a novel therapeutic approach within the drug-conjugate class of anti-cancer therapies with parallels to Antibody-Drug Conjugates (ADCs).

Company Info

NUVATION BIO INC

357 Tehama Street, Floor 3

San Francisco CALIFORNIA 94103

P: 14157543517

CEO: David Hung

Employees: 53

Website: https://www.nuvationbio.com/